{"id":"ivig-infusion","safety":{"commonSideEffects":[{"rate":"15-30","effect":"Headache"},{"rate":"5-15","effect":"Fever"},{"rate":"5-10","effect":"Chills"},{"rate":"5-10","effect":"Myalgia"},{"rate":"5-15","effect":"Infusion site reactions"},{"rate":"0.1-1","effect":"Aseptic meningitis"},{"rate":"0.1-1","effect":"Thromboembolism"},{"rate":"0.1-1","effect":"Acute kidney injury"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"IVIG is a blood product containing immunoglobulin G (IgG) antibodies extracted and purified from the plasma of thousands of healthy donors. It works through multiple mechanisms including direct neutralization of pathogens and toxins, opsonization to enhance clearance, blockade of Fc receptors on immune cells to reduce inflammation, and provision of anti-idiotypic antibodies that suppress autoimmune responses. The exact therapeutic mechanism varies by indication but generally involves immune modulation and passive antibody replacement.","oneSentence":"IVIG (intravenous immunoglobulin) provides passive immunity by delivering pooled antibodies from multiple donors to modulate immune responses and neutralize pathogens or autoimmune mediators.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:17:33.161Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Primary immunodeficiency disorders"},{"name":"Chronic inflammatory demyelinating polyneuropathy (CIDP)"},{"name":"Multifocal motor neuropathy"},{"name":"Immune thrombocytopenia (ITP)"},{"name":"Kawasaki disease"}]},"trialDetails":[{"nctId":"NCT06290141","phase":"PHASE3","title":"A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)","status":"RECRUITING","sponsor":"Sanofi","startDate":"2024-08-21","conditions":"Chronic Inflammatory Demyelinating Polyneuropathy","enrollment":160},{"nctId":"NCT06980480","phase":"PHASE3","title":"A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma","status":"RECRUITING","sponsor":"Takeda","startDate":"2026-01-14","conditions":"Multiple Myeloma, Secondary Immunodeficiency","enrollment":183},{"nctId":"NCT06859424","phase":"PHASE2","title":"A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation","status":"RECRUITING","sponsor":"Center for International Blood and Marrow Transplant Research","startDate":"2025-07-25","conditions":"AML (Acute Myelogenous Leukemia), Acute Lymphoid Leukemia (ALL), Acute Leukemia (Category)","enrollment":358},{"nctId":"NCT07299695","phase":"PHASE3","title":"Intravenous Immunoglobulin for the Treatment of Acute Exacerbations of Idiopathic Pulmonary Fibrosis","status":"RECRUITING","sponsor":"Argyrios Tzouvelekis","startDate":"2026-01-25","conditions":"Idiopathic Pulmonary Fibrosis, Acute Exacerbation of Idiopathic Pulmonary Fibrosis","enrollment":196},{"nctId":"NCT06752356","phase":"PHASE3","title":"A Study Investigating Intravenous Human Normal Immune Globulin (IGIV) 10% in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)","status":"RECRUITING","sponsor":"Kedrion S.p.A.","startDate":"2026-04","conditions":"Chronic Inflammatory Demyelinating Polyneuropathy","enrollment":161},{"nctId":"NCT06742190","phase":"PHASE3","title":"A Study to Assess the Efficacy and Safety of Empasiprubart Versus IVIg in Adults With Multifocal Motor Neuropathy","status":"RECRUITING","sponsor":"argenx","startDate":"2024-12-18","conditions":"Multifocal Motor Neuropathy (MMN), MMN","enrollment":115},{"nctId":"NCT07410039","phase":"PHASE4","title":"Therapy in the Acute Phase of NMOSD: A Multicenter Prospective Real-World Study","status":"RECRUITING","sponsor":"Chinese PLA General Hospital","startDate":"2026-02-01","conditions":"Neuromyelitis Optica Spectrum Disorder Attack","enrollment":200},{"nctId":"NCT06918990","phase":"PHASE2","title":"Treatment of Antibody-Mediated Rejection (ABMR) With CarBel","status":"NOT_YET_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2026-04-15","conditions":"Kidney Transplant Rejection","enrollment":25},{"nctId":"NCT04609761","phase":"PHASE2","title":"Open-label Trial of IVIG in Children With PANS","status":"COMPLETED","sponsor":"Göteborg University","startDate":"2021-01-12","conditions":"PANS Pediatric Acute-Onset Neuropsychiatric Syndrome","enrollment":17},{"nctId":"NCT06920004","phase":"PHASE3","title":"A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP","status":"RECRUITING","sponsor":"argenx","startDate":"2025-08-22","conditions":"Chronic Inflammatory Demyelinating Polyneuropathy, CIDP, CIDP - Chronic Inflammatory Demyelinating Polyneuropathy","enrollment":218},{"nctId":"NCT03849651","phase":"PHASE2","title":"TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2019-01-31","conditions":"Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS)","enrollment":69},{"nctId":"NCT05832034","phase":"PHASE2, PHASE3","title":"Add-on Intravenous Immunoglobulins in Early Myositis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2021-09-13","conditions":"Inflammatory Myopathy, Idiopathic, Dermatomyositis, Antisynthetase Syndrome","enrollment":44},{"nctId":"NCT05662228","phase":"PHASE2","title":"Therapies for Down Syndrome Regression Disorder","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Colorado, Denver","startDate":"2023-06-29","conditions":"Down Syndrome, Regression","enrollment":66},{"nctId":"NCT06599697","phase":"PHASE2","title":"The MIGHT Trial - An Exploratory Clinical Trial of IVIG in Anti-HMGCR Immune Mediated Necrotizing Myopathy","status":"RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2025-10-27","conditions":"Anti-3-hydroxy-3-methylglutaryl-CoA Reductase (HMGCR) Immune-Mediated Necrotizing Myopathy","enrollment":12},{"nctId":"NCT06565078","phase":"","title":"A Database Survey to Evaluate the Safety of Immune Globulin Subcutaneous (Human), 20% Solution in Participants With Primary Immunodeficiency","status":"RECRUITING","sponsor":"Takeda","startDate":"2025-02-17","conditions":"Primary Immunodeficiency Diseases (PID)","enrollment":100},{"nctId":"NCT04224558","phase":"PHASE1, PHASE2","title":"Stem Cell Transplantation in Crohn's Disease","status":"RECRUITING","sponsor":"Cedars-Sinai Medical Center","startDate":"2019-11-15","conditions":"Crohn Disease","enrollment":15},{"nctId":"NCT06798012","phase":"PHASE2","title":"A Study of TAK-411 in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)","status":"RECRUITING","sponsor":"Takeda","startDate":"2025-05-14","conditions":"Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)","enrollment":36},{"nctId":"NCT05755035","phase":"PHASE2, PHASE3","title":"A Study About How TAK-881 is Processed by the Body and Side Effects in People With Primary Immunodeficiency Diseases","status":"COMPLETED","sponsor":"Takeda","startDate":"2023-10-24","conditions":"Primary Immunodeficiency Diseases (PID)","enrollment":65},{"nctId":"NCT05952804","phase":"PHASE2","title":"IVIG for Infection Prevention After CAR-T-Cell Therapy","status":"RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2024-06-10","conditions":"Hematologic Malignancies","enrollment":150},{"nctId":"NCT04910269","phase":"PHASE3","title":"Outpatient Treatment With Anti-Coronavirus Immunoglobulin","status":"RECRUITING","sponsor":"University of Minnesota","startDate":"2021-08-06","conditions":"COVID, SARS-CoV2 Infection, Covid19","enrollment":820},{"nctId":"NCT06747351","phase":"PHASE3","title":"A Study to Compare TAK-881 and HYQVIA in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)","status":"RECRUITING","sponsor":"Takeda","startDate":"2025-05-06","conditions":"Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)","enrollment":59},{"nctId":"NCT06962631","phase":"PHASE3","title":"V-IMMUNE® for Immune Thrombocytopenia","status":"RECRUITING","sponsor":"On Pharma Importadora, Exportadora e Distribuidora de Medicamentos LTDA.","startDate":"2025-07-18","conditions":"Immune Thrombocytopenia (ITP)","enrollment":31},{"nctId":"NCT06954441","phase":"PHASE3","title":"V-IMMUNE: A Novel Immunoglobulin Therapy for Immunodeficiency","status":"RECRUITING","sponsor":"On Pharma Importadora, Exportadora e Distribuidora de Medicamentos LTDA.","startDate":"2025-08-15","conditions":"Immunodeficiencies, Primary Immunodeficiencies (PID), Agammaglobulinemia","enrollment":50},{"nctId":"NCT04944979","phase":"PHASE3","title":"Clinical Assessment of Pharmacokinetics, Efficacy, and Safety of 10% IVIg in Pediatric PID Patients (KIDCARES10)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Kedrion S.p.A.","startDate":"2021-03-31","conditions":"Primary Immunodeficiency Disease","enrollment":30},{"nctId":"NCT03292861","phase":"PHASE2","title":"The Effect and Safety Profile of Thymoglobulin® in Primary Cardiac Transplant Recipients","status":"ENROLLING_BY_INVITATION","sponsor":"Cedars-Sinai Medical Center","startDate":"2018-09-13","conditions":"Heart Transplantation","enrollment":60},{"nctId":"NCT04153422","phase":"PHASE2","title":"IVIG in the Treatment of Autoimmune Small Fiber Neuropathy With TS-HDS, FGFR-3, or Plexin D1 Antibodies","status":"RECRUITING","sponsor":"Endeavor Health","startDate":"2023-12-15","conditions":"Small Fiber Neuropathy, Autoimmune Small Fiber Neuropathy, Inflammatory Polyneuropathy","enrollment":20},{"nctId":"NCT01596335","phase":"PHASE3","title":"Clinical Study of TA-650 in Patients With Refractory Kawasaki Disease","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2012-05","conditions":"Kawasaki Disease Refractory to Initial Therapy With Intravenous Immunoglobulin","enrollment":31},{"nctId":"NCT04078568","phase":"PHASE3","title":"Efficacy of Immunoglobulin Plus Prednisolone in Reducing Coronary Artery Lesion in Patients With Kawasaki Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Hospital of Fudan University","startDate":"2020-01-15","conditions":"Kawasaki Disease","enrollment":3208},{"nctId":"NCT06958796","phase":"PHASE4","title":"Strategic Help With Immunoglobulin to Enhance Protect Against Late Disease (CMV)","status":"RECRUITING","sponsor":"Camille N. Kotton, MD","startDate":"2025-11-27","conditions":"Cytomegalovirus, Organ Transplant, Kidney Transplant; Complications","enrollment":80},{"nctId":"NCT04422912","phase":"PHASE1, PHASE2","title":"A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)","status":"RECRUITING","sponsor":"Cabaletta Bio","startDate":"2020-09-29","conditions":"Pemphigus Vulgaris","enrollment":40},{"nctId":"NCT05645107","phase":"PHASE3","title":"A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma","status":"RECRUITING","sponsor":"Grifols Therapeutics LLC","startDate":"2022-12-26","conditions":"Hypogammaglobulinemia, Bacterial Infections, B-cell Chronic Lymphocytic Leukemia","enrollment":386},{"nctId":"NCT07076446","phase":"PHASE4","title":"An Open-label, Multicenter Study to Assess the Pharmacokinetics (PK), Safety, and Tolerability of Subcutaneous IgPro20 in Immunoglobulin (IG) Treatment-naïve Participants With Primary Immunodeficiency (PID)","status":"RECRUITING","sponsor":"CSL Behring","startDate":"2025-07-15","conditions":"Primary Immunodeficiency","enrollment":8},{"nctId":"NCT05494593","phase":"PHASE4","title":"A Study of ELAPRASE in Treatment-naïve Participants With Hunter Syndrome (Mucopolysaccharidosis [MPS] II)","status":"WITHDRAWN","sponsor":"Takeda","startDate":"2023-02-28","conditions":"Mucopolysaccharidosis (MPS), Hunter Syndrome","enrollment":""},{"nctId":"NCT02176863","phase":"PHASE2, PHASE3","title":"Study of the Efficacy and Safety of Immune Globulin Intravenous (Human) Flebogamma® 5% Dual Inactivation and Filtration (DIF) in Participants With Post-polio Syndrome","status":"TERMINATED","sponsor":"Instituto Grifols, S.A.","startDate":"2014-09-23","conditions":"Post-polio Syndrome","enrollment":191},{"nctId":"NCT05084053","phase":"PHASE3","title":"A Study of TAK-771 in Japanese Participants With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) and Multifocal Motor Neuropathy (MMN)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Takeda","startDate":"2022-01-19","conditions":"Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP), Multifocal Motor Neuropathy (MMN)","enrollment":26},{"nctId":"NCT04701034","phase":"PHASE2","title":"Intravenous Immunoglobulin and Prednisolone for RPL After ART.","status":"COMPLETED","sponsor":"Aalborg University Hospital","startDate":"2021-01-28","conditions":"Habitual Abortion, Recurrent Pregnancy Loss, Fertility Disorders","enrollment":80},{"nctId":"NCT07231523","phase":"PHASE3","title":"EFG vs IVIG in TAMG","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2025-12-01","conditions":"Efgartigimod, Intravenous Immunoglobulin, Myasthenia Gravis Associated With Thymoma","enrollment":64},{"nctId":"NCT05513586","phase":"PHASE3","title":"A Study to Evaluate the Long-term Safety of TAK-771 in Japanese Primary Immunodeficiency Disease (PID) Participants","status":"COMPLETED","sponsor":"Takeda","startDate":"2022-09-13","conditions":"Primary Immunodeficiency Diseases (PID)","enrollment":15},{"nctId":"NCT06935266","phase":"PHASE1","title":"A Study of TAK-881 With and Without Ramp-Up Dosing in Healthy Adults","status":"COMPLETED","sponsor":"Takeda","startDate":"2025-04-22","conditions":"Healthy Volunteers","enrollment":64},{"nctId":"NCT07193953","phase":"PHASE1","title":"Intravenous Immunoglobulin (IVIG) and Blood-Brain Barrier Disruption in Amyotrophic Lateral Sclerosis (ALS)","status":"RECRUITING","sponsor":"Sunnybrook Health Sciences Centre","startDate":"2025-04-15","conditions":"Amyotrophic Lateral Sclerosis, ALS","enrollment":6},{"nctId":"NCT06753955","phase":"PHASE1","title":"Phase 1 Study of ART5803 Safety and PK After IVIG in Healthy Participants","status":"ACTIVE_NOT_RECRUITING","sponsor":"Arialys Therapeutics","startDate":"2025-03-18","conditions":"Autoimmune Encephalitis Caused by N-Methyl D-Aspartate Receptor Antibody, Autoimmune Encephalitis Caused by N-Methyl D-Aspartate Receptor Antibody (Disorder), Autoimmune Encephalitis","enrollment":6},{"nctId":"NCT04480450","phase":"PHASE2","title":"Rituximab in Chronic Inflammatory Demyelinating Polyneuropathy","status":"WITHDRAWN","sponsor":"University of Kansas Medical Center","startDate":"2025-07","conditions":"Chronic Inflammatory Demyelinating Polyneuropathy","enrollment":""},{"nctId":"NCT06895967","phase":"PHASE1","title":"A Study of TAK-881 and HyQvia in Healthy Adults","status":"COMPLETED","sponsor":"Takeda","startDate":"2025-03-24","conditions":"Healthy Volunteers","enrollment":30},{"nctId":"NCT06765161","phase":"PHASE3","title":"Efgartigimod in IVIG Dependent Myasthenia Gravis Patients","status":"RECRUITING","sponsor":"Clinique Neuro-Outaouais","startDate":"2025-02-06","conditions":"Myasthaenia Gravis","enrollment":30},{"nctId":"NCT04565015","phase":"PHASE3","title":"Study of Immune Globulin Intravenous (Human) GC5107 in Pediatric Subjects With Primary Humoral Immunodeficiency","status":"ACTIVE_NOT_RECRUITING","sponsor":"GC Biopharma Corp","startDate":"2020-12-21","conditions":"Primary Immune Deficiency","enrollment":24},{"nctId":"NCT07068126","phase":"NA","title":"Management of Children With Persistent ITP, A Novel Approach","status":"RECRUITING","sponsor":"Assiut University","startDate":"2025-01-01","conditions":"Persistent Immune Thrombocytopenia","enrollment":20},{"nctId":"NCT04935177","phase":"PHASE3","title":"Renal Function in Highly Sensitized Patients 1 Year After Desensitization With Imlifidase Prior to DD Kidney Tx","status":"COMPLETED","sponsor":"Hansa Biopharma AB","startDate":"2021-10-14","conditions":"Kidney Transplantation in Highly Sensitized Patients","enrollment":64},{"nctId":"NCT04400994","phase":"PHASE2","title":"IVIG With Rituximab vs Rituximab as First Line Treatment of Pemphigus","status":"ACTIVE_NOT_RECRUITING","sponsor":"The University of Hong Kong","startDate":"2020-06-20","conditions":"Pemphigus","enrollment":20},{"nctId":"NCT00199862","phase":"NA","title":"Safety Study of Radio-labeled huA33 Antibody in Colorectal Cancer","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2004-02","conditions":"Colorectal Neoplasms, Colorectal Cancer, Colorectal Tumor","enrollment":30},{"nctId":"NCT07017036","phase":"PHASE3","title":"Efficacy, Safety and Pharmacokinetic of Virchow IVIG in PID Patients","status":"NOT_YET_RECRUITING","sponsor":"Virchow Group","startDate":"2025-07-01","conditions":"Primary Immunodeficiency Diseases (PID)","enrollment":44},{"nctId":"NCT03866577","phase":"PHASE1, PHASE2","title":"Safety and Tolerability of M254 in Healthy Volunteers and Immune Thrombocytopenic Purpura (ITP) Patients","status":"TERMINATED","sponsor":"Momenta Pharmaceuticals, Inc.","startDate":"2018-12-21","conditions":"Immune Thrombocytopenic Purpura (ITP)","enrollment":50},{"nctId":"NCT06076642","phase":"PHASE3","title":"A Study About the Long-Term Safety of TAK-881 in People With Primary Immunodeficiency Diseases","status":"RECRUITING","sponsor":"Takeda","startDate":"2024-11-04","conditions":"Primary Immunodeficiency Diseases (PID)","enrollment":39},{"nctId":"NCT06955793","phase":"","title":"Expanded Access to TAK-881 for Children and Teenagers With Primary Immunodeficiency Diseases in the USA","status":"AVAILABLE","sponsor":"Takeda","startDate":"","conditions":"Primary Immunodeficiency Diseases (PIDD)","enrollment":""},{"nctId":"NCT03961009","phase":"PHASE3","title":"Clinical Assessment of Pharmacokinetics, Efficacy, and Safety of 10% IVIg in PID Patients","status":"COMPLETED","sponsor":"Kedrion S.p.A.","startDate":"2019-04-30","conditions":"Primary Immunodeficiency Disease","enrollment":47},{"nctId":"NCT03994783","phase":"PHASE3","title":"Transplant Antibody-Mediated Rejection: Guiding Effective Treatments","status":"TERMINATED","sponsor":"Imperial College London","startDate":"2019-07-17","conditions":"Kidney Transplant Rejection, Antibody-mediated Rejection","enrollment":3},{"nctId":"NCT03194815","phase":"PHASE2","title":"IVIG and Rituximab in Antibody-associated Psychosis - SINAPPS2","status":"RECRUITING","sponsor":"University of Cambridge","startDate":"2017-11-01","conditions":"Psychosis, Autoimmune Encephalitis","enrollment":70},{"nctId":"NCT04842643","phase":"PHASE3","title":"An Extension Study of TAK-664 for Japanese People With Primary Immunodeficiency Disease","status":"COMPLETED","sponsor":"Takeda","startDate":"2021-04-27","conditions":"Primary Immunodeficiency Disease","enrollment":12},{"nctId":"NCT04634435","phase":"PHASE1","title":"Autologous Memory-like NK Cell Therapy With BHV-1100 and Low Dose IL-2 in Multiple Myeloma Patients","status":"COMPLETED","sponsor":"Biohaven Pharmaceuticals, Inc.","startDate":"2021-10-21","conditions":"Multiple Myeloma","enrollment":7},{"nctId":"NCT03092180","phase":"","title":"Optimizing Treatment on Idiopathic Inflammatory Myopathies","status":"RECRUITING","sponsor":"University of Sao Paulo","startDate":"2005-01","conditions":"Idiopathic Inflammatory Myopathies","enrollment":60},{"nctId":"NCT05150340","phase":"PHASE3","title":"A Study of TAK-771 in Japanese People With Primary Immunodeficiency Diseases (PID)","status":"COMPLETED","sponsor":"Takeda","startDate":"2022-01-24","conditions":"Primary Immunodeficiency Diseases (PID)","enrollment":16},{"nctId":"NCT05422365","phase":"PHASE3","title":"Intravenous Immunoglobulin (IVIG, Bioven) Efficacy and Safety in Chronic Primary Immune Thrombocytopenia (ITP) in Adults","status":"COMPLETED","sponsor":"Biopharma Plasma LLC","startDate":"2022-07-26","conditions":"Primary Immune Thrombocytopenia","enrollment":32},{"nctId":"NCT03919773","phase":"PHASE1, PHASE2","title":"IVIG (Gamunex-C) Treatment Study for POTS Subjects","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2018-10-29","conditions":"Postural Tachycardia Syndrome","enrollment":30},{"nctId":"NCT02955355","phase":"PHASE3","title":"Long-Term Tolerability and Safety of HYQVIA/HyQvia in CIDP","status":"COMPLETED","sponsor":"Baxalta now part of Shire","startDate":"2016-11-14","conditions":"Chronic Inflammatory Demyelinating Polyradiculoneuropathy","enrollment":85},{"nctId":"NCT04302805","phase":"PHASE3","title":"rATG Versus rATG Combined With Intravenous Immunoglobulin (IVIG) Induction Immunosuppression in HLA Incompatible Transplantation (INHIBIT)","status":"COMPLETED","sponsor":"Institute for Clinical and Experimental Medicine","startDate":"2020-07-27","conditions":"Kidney Transplantation","enrollment":17},{"nctId":"NCT01184846","phase":"PHASE3","title":"Study of Efficacy and Safety of Privigen in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy","status":"COMPLETED","sponsor":"CSL Behring","startDate":"2010-11","conditions":"Chronic Inflammatory Demyelinating Polyneuropathy","enrollment":31},{"nctId":"NCT04346108","phase":"PHASE3","title":"A Study of Immune Globulin Subcutaneous (Human), 20% Solution (IGSC, 20%) in Japanese Participants With Primary Immunodeficiency Diseases (PID)","status":"COMPLETED","sponsor":"Baxalta now part of Shire","startDate":"2020-08-11","conditions":"Primary Immunodeficiency Diseases (PID)","enrollment":17},{"nctId":"NCT00845650","phase":"PHASE1, PHASE2","title":"Safety and Pharmacokinetics Study of Anthrax Immune Globulin Intravenous (AIGIV)","status":"COMPLETED","sponsor":"Emergent BioSolutions","startDate":"2009-02","conditions":"Anthrax","enrollment":129},{"nctId":"NCT04656184","phase":"PHASE3","title":"A Trial Comparing the Efficacy and Safety of Anakinra Versus Intravenous Immunoglobulin (IVIG) Retreatment, in Patients With Kawasaki Disease Who Failed to Respond to Initial Standard IVIG Treatment","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2023-10-20","conditions":"Kawasaki Disease","enrollment":84},{"nctId":"NCT04137224","phase":"PHASE2","title":"Safety and Pharmacokinetics of IgPro20 and IgPro10 in Adults With Systemic Sclerosis (SSc)","status":"COMPLETED","sponsor":"CSL Behring","startDate":"2019-09-19","conditions":"Diffuse Cutaneous Systemic Sclerosis","enrollment":27},{"nctId":"NCT04400058","phase":"PHASE3","title":"Octagam 10% Therapy in COVID-19 Patients With Severe Disease Progression","status":"COMPLETED","sponsor":"Octapharma","startDate":"2020-06-01","conditions":"Covid-19","enrollment":207},{"nctId":"NCT05059977","phase":"PHASE1","title":"A Study of TAK-881 in Healthy Adults","status":"COMPLETED","sponsor":"Takeda","startDate":"2021-10-12","conditions":"Healthy Volunteers","enrollment":24},{"nctId":"NCT04381936","phase":"PHASE3","title":"Randomised Evaluation of COVID-19 Therapy","status":"RECRUITING","sponsor":"University of Oxford","startDate":"2020-03-19","conditions":"Severe Acute Respiratory Syndrome","enrollment":70000},{"nctId":"NCT06183008","phase":"PHASE4","title":"IVIG in Painful Sensory Neuropathy","status":"NOT_YET_RECRUITING","sponsor":"Sorlandet Hospital HF","startDate":"2024-02","conditions":"Sensory Neuropathy, Small Fiber Neuropathy","enrollment":20},{"nctId":"NCT04578535","phase":"PHASE1","title":"A Study to Assess the Tolerability, Safety, and Pharmacokinetics of Subcutaneous Immune Globulin Infusion 10% (Human) With Recombinant Human Hyaluronidase (HYQVIA/HyQvia) With Ramp-up and No Ramp-up Dosing in Healthy Adult Participants","status":"COMPLETED","sponsor":"Baxalta now part of Shire","startDate":"2020-10-27","conditions":"Healthy Volunteers","enrollment":51},{"nctId":"NCT06150833","phase":"PHASE3","title":"Efficacy and Safety and Pharmacokinetics of Boya IVIG","status":"UNKNOWN","sponsor":"Azidus Brasil","startDate":"2024-04-01","conditions":"Primary Immunodeficiency Disease","enrollment":50},{"nctId":"NCT03277313","phase":"PHASE3","title":"Efficacy, Safety, Tolerability, Immunogenicity and Pharmacokinetic Evaluation of HYQVIA in Pediatric PIDD Subjects","status":"COMPLETED","sponsor":"Baxalta now part of Shire","startDate":"2017-09-25","conditions":"Primary Immunodeficiency Diseases (PID)","enrollment":44},{"nctId":"NCT04566692","phase":"PHASE4","title":"A Study to Evaluate IGSC 20% Biweekly Dosing in Treatment-Experienced Participants and Loading/Maintenance Dosing in Treatment-Naïve Participants With Primary Immunodeficiency","status":"COMPLETED","sponsor":"Grifols Therapeutics LLC","startDate":"2020-11-24","conditions":"Primary Immunodeficiency","enrollment":33},{"nctId":"NCT03772717","phase":"NA","title":"Non-invasive Vagus Nerve Stimulation (nVNS) in Pediatric Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)","status":"TERMINATED","sponsor":"Emory University","startDate":"2022-02-22","conditions":"Chronic Inflammatory Demyelinating Polyneuropathy","enrollment":2},{"nctId":"NCT04561115","phase":"PHASE3","title":"A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Immune Globulin (Human) 10% (Gamunex-C) PEG Process (IVIG-PEG) Compared to Gamunex-C in Participants With Primary Humoral Immunodeficiency","status":"COMPLETED","sponsor":"Grifols Therapeutics LLC","startDate":"2020-09-02","conditions":"Primary Immunodeficiency","enrollment":33},{"nctId":"NCT02549170","phase":"PHASE3","title":"A Study of HyQvia and Gammagard Liquid (Kiovig) in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)","status":"COMPLETED","sponsor":"Baxalta now part of Shire","startDate":"2015-12-15","conditions":"Chronic Inflammatory Demyelinating Polyradiculoneuropathy","enrollment":138},{"nctId":"NCT04859829","phase":"","title":"Autoimmune Gastrointestinal Dysmotility: Symptoms, Pathogenesis and Treatment","status":"TERMINATED","sponsor":"Johns Hopkins University","startDate":"2021-04-22","conditions":"Dysmotility Syndrome, Autoimmunity","enrollment":1},{"nctId":"NCT01376778","phase":"PHASE3","title":"A Randomized Trial to Prevent Congenital Cytomegalovirus (CMV)","status":"COMPLETED","sponsor":"The George Washington University Biostatistics Center","startDate":"2012-04","conditions":"Congenital Cytomegalovirus Infection, Maternal Cytomegalovirus Infection","enrollment":399},{"nctId":"NCT03037359","phase":"","title":"A Study About Low Blood Pressure in Patients With Primary Immunodeficiency Disease Treated With Immune Globulin Products","status":"UNKNOWN","sponsor":"ADMA Biologics, Inc.","startDate":"2016-12","conditions":"Primary Immune Deficiency Disorder","enrollment":200},{"nctId":"NCT03116347","phase":"PHASE4","title":"Post-Authorization Safety, Tolerability and Immunogenicity Evaluation of HyQvia in Pediatric PIDD Subjects","status":"COMPLETED","sponsor":"Baxalta now part of Shire","startDate":"2017-05-30","conditions":"Primary Immunodeficiency Diseases (PID)","enrollment":42},{"nctId":"NCT04741139","phase":"PHASE1","title":"Post IVIG Medication in Children With Immune Thrombocytopenia","status":"UNKNOWN","sponsor":"Baylor College of Medicine","startDate":"2021-09-02","conditions":"Immune Thrombocytopenia","enrollment":20},{"nctId":"NCT05494619","phase":"PHASE3","title":"A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab in Participants With Guillain-Barré Syndrome (GBS)","status":"WITHDRAWN","sponsor":"Hoffmann-La Roche","startDate":"2022-11-30","conditions":"Guillain-Barré Syndrome","enrollment":""},{"nctId":"NCT04847141","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of C19-IG 20% in SARS-CoV-2 Infected Asymptomatic Ambulatory Outpatients","status":"TERMINATED","sponsor":"Grifols Therapeutics LLC","startDate":"2021-04-28","conditions":"COVID-19, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection","enrollment":465},{"nctId":"NCT01300728","phase":"PHASE2","title":"Study of Intravenous Immunoglobulin in Amnestic Mild Cognitive Impairment","status":"COMPLETED","sponsor":"Sutter Health","startDate":"2011-01-01","conditions":"Mild Cognitive Impairment","enrollment":52},{"nctId":"NCT02593188","phase":"","title":"Non-Interventional Post-Marketing Safety Study on the Long-Term Safety of HYQVIA (Global)","status":"COMPLETED","sponsor":"Baxalta now part of Shire","startDate":"2015-11-12","conditions":"Primary Immunodeficiency Diseases (PID)","enrollment":264},{"nctId":"NCT04891172","phase":"PHASE2, PHASE3","title":"Anti COVID 19 Hyperimmune Intravenous Immunoglobulin (C-IVIG) Therapy for Severe COVID-19 Patients","status":"UNKNOWN","sponsor":"Dow University of Health Sciences","startDate":"2021-08-01","conditions":"Covid19","enrollment":310},{"nctId":"NCT04834908","phase":"PHASE1, PHASE2","title":"Evaluation of Equine Antibody Treatment in Patients With COVID 19 Infection","status":"TERMINATED","sponsor":"Bharat Serums and Vaccines Limited","startDate":"2021-07-27","conditions":"SARS-CoV-2 Infection","enrollment":7},{"nctId":"NCT04480424","phase":"PHASE2","title":"Study to Evaluate the Safety and Efficacy of High Dose Intravenous Immune Globulin (IVIG) Plus Standard Medical Treatment (SMT) Versus SMT Alone in Participants in Intensive Care Unit (ICU) With Coronavirus Disease (COVID-19)","status":"COMPLETED","sponsor":"Grifols Therapeutics LLC","startDate":"2020-09-17","conditions":"COVID-19","enrollment":100},{"nctId":"NCT05070455","phase":"PHASE4","title":"An Open Label, Multicenter Study to Evaluate the Pharmacokinetics, Efficacy and Safety of ASCENIV™ (IGIV) in Pediatric Subjects With Primary Immunodeficiency Diseases (PIDD)","status":"UNKNOWN","sponsor":"ADMA Biologics, Inc.","startDate":"2022-09-01","conditions":"Primary Immune Deficiency","enrollment":12},{"nctId":"NCT04546581","phase":"PHASE3","title":"Inpatient Treatment of COVID-19 With Anti-Coronavirus Immunoglobulin (ITAC)","status":"COMPLETED","sponsor":"University of Minnesota","startDate":"2020-10-08","conditions":"COVID, COVID-19, SARS-CoV-2","enrollment":593},{"nctId":"NCT02184741","phase":"PHASE3","title":"A Study of the Efficacy and Safety of GB-0998 in Patients With Unexplained Recurrent Miscarriage","status":"COMPLETED","sponsor":"Japan Blood Products Organization","startDate":"2014-06-03","conditions":"Recurrent Miscarriage","enrollment":99},{"nctId":"NCT02728752","phase":"PHASE3","title":"Study Evaluating Efficacy and Safety of Octagam 10% in Patients With Dermatomyositis (Idiopathic Inflammatory Myopathy)","status":"COMPLETED","sponsor":"Octapharma","startDate":"2017-02-27","conditions":"Dermatomyositis","enrollment":95},{"nctId":"NCT03065244","phase":"PHASE3","title":"KIDCARE (Kawasaki Disease Comparative Effectiveness Trial)","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2017-02-17","conditions":"Mucocutaneous Lymph Node Syndrome","enrollment":105},{"nctId":"NCT00000720","phase":"PHASE3","title":"A Double-Blind, Placebo-Controlled Trial To Evaluate Intravenous Gamma Globulin in Children With Symptomatic HIV Infection Receiving Zidovudine","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":250},{"nctId":"NCT02659891","phase":"PHASE1","title":"IVIg to Treat BK Viremia in Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2016-05","conditions":"Kidney Transplantation, BK Virus, Isoantibodies","enrollment":16},{"nctId":"NCT00538915","phase":"PHASE3","title":"Open Label, Phase III Study of NABI-IGIV 10% [Immune Globulin Intravenous(Human), 10%] In Subjects With Primary Immune Deficiency Disorders (PIDD)","status":"COMPLETED","sponsor":"ADMA Biologics, Inc.","startDate":"2007-09","conditions":"Primary Immune Deficiency Disorders (PIDD)","enrollment":63}],"_emaApprovals":[],"_faersSignals":[{"count":3,"reaction":"HEADACHE"},{"count":3,"reaction":"MALAISE"},{"count":3,"reaction":"SWELLING FACE"},{"count":2,"reaction":"ABDOMINAL PAIN UPPER"},{"count":2,"reaction":"COUGH"},{"count":2,"reaction":"DEHYDRATION"},{"count":2,"reaction":"DYSPNOEA"},{"count":2,"reaction":"ERYTHEMA"},{"count":2,"reaction":"FALL"},{"count":2,"reaction":"HYPERSENSITIVITY"}],"_approvalHistory":[],"publicationCount":358,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Intravenous Immunoglobulin","IgG"],"phase":"phase_3","status":"active","brandName":"IVIG infusion","genericName":"IVIG infusion","companyName":"McMaster University","companyId":"mcmaster-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"IVIG (intravenous immunoglobulin) provides passive immunity by delivering pooled antibodies from multiple donors to modulate immune responses and neutralize pathogens or autoimmune mediators. Used for Primary immunodeficiency disorders, Chronic inflammatory demyelinating polyneuropathy (CIDP), Multifocal motor neuropathy.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}